AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have earned a consensus recommendation of “Moderate Buy” from the eleven ratings firms that are covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $36.20.

Several research firms have recently issued reports on ANAB. Truist Financial decreased their price objective on shares of AnaptysBio from $30.00 to $20.00 and set a “hold” rating for the company in a research report on Wednesday, December 18th. UBS Group lifted their price target on AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. Wells Fargo & Company increased their price objective on AnaptysBio from $40.00 to $51.00 and gave the company an “overweight” rating in a report on Thursday, February 13th. Guggenheim cut their target price on AnaptysBio from $90.00 to $36.00 and set a “buy” rating on the stock in a research report on Thursday, December 12th. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $19.00 price target on shares of AnaptysBio in a report on Tuesday, February 4th.

AnaptysBio Stock Performance

Shares of AnaptysBio stock opened at $17.20 on Tuesday. The business has a 50-day simple moving average of $15.87 and a 200-day simple moving average of $25.17. AnaptysBio has a one year low of $12.21 and a one year high of $41.31. The company has a market cap of $523.38 million and a PE ratio of -2.83.

Insider Activity

In other AnaptysBio news, Director Ecor1 Capital, Llc acquired 65,184 shares of the company’s stock in a transaction on Monday, December 30th. The shares were bought at an average cost of $12.92 per share, for a total transaction of $842,177.28. Following the completion of the purchase, the director now owns 7,860,180 shares in the company, valued at $101,553,525.60. This trade represents a 0.84 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 33.70% of the company’s stock.

Hedge Funds Weigh In On AnaptysBio

A number of hedge funds and other institutional investors have recently made changes to their positions in ANAB. China Universal Asset Management Co. Ltd. lifted its position in AnaptysBio by 11.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 644 shares during the period. Virtus ETF Advisers LLC raised its stake in shares of AnaptysBio by 24.7% during the fourth quarter. Virtus ETF Advisers LLC now owns 4,733 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 936 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of AnaptysBio by 3.8% during the fourth quarter. Rhumbline Advisers now owns 30,077 shares of the biotechnology company’s stock worth $398,000 after purchasing an additional 1,111 shares during the period. Tower Research Capital LLC TRC grew its position in AnaptysBio by 131.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 1,531 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in AnaptysBio by 21.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,012 shares of the biotechnology company’s stock valued at $199,000 after buying an additional 2,701 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.